| Item Type | Name |
|
Concept
|
Gene Expression Regulation, Enzymologic
|
|
Concept
|
Gene Expression Regulation, Neoplastic
|
|
Academic Article
|
The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.
|
|
Academic Article
|
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
|
|
Academic Article
|
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration.
|
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
|
|
Academic Article
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
|
Academic Article
|
FYN is overexpressed in human prostate cancer.
|
|
Academic Article
|
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
|
|
Academic Article
|
Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.
|
|
Academic Article
|
PAX3 and SOX10 activate MET receptor expression in melanoma.
|
|
Academic Article
|
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
|
|
Academic Article
|
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.
|
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
|
Academic Article
|
PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
|
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
|
|
Academic Article
|
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.
|
|
Academic Article
|
EphB4: A promising target for upper aerodigestive malignancies.
|
|
Academic Article
|
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
|
|
Academic Article
|
Therapeutic targeting of miRNA-216b in cancer.
|
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
|
Academic Article
|
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
|
|
Academic Article
|
Activating p53 function by targeting RLIP.
|
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
MicroRNA-1: Diverse role of a small player in multiple cancers.
|
|
Academic Article
|
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
|
|
Academic Article
|
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
|
Academic Article
|
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
|